Vice President & General Manager, EU North

About BridgeBio Pharma, Inc. 

BridgeBio is a biopharmaceutical company dedicated to discovering, developing, and delivering transformative medicines for patients living with genetic diseases and genetically defined cancers. Since our founding in 2015, we have built a diverse portfolio of more than 20 drug development programs, ranging from early discovery to late-stage clinical trials, across multiple therapeutic areas including precision oncology, cardiology, endocrinology, neurology, and renal disease. We have already achieved regulatory approval for three therapies and continue to advance promising science from academia into meaningful treatments for patients worldwide.  

Who We Are  

BridgeBio is a global biotechnology company with our Global Headquarters located in San Francisco, USA, and our International HQ located in Zug, Switzerland. Since establishing our European presence in 2021, we’ve been building empowered, high-performing teams across countries —with experienced colleagues who move quickly, take ownership, and are fueling the company’s international growth.  

At BridgeBio, you’ll find an energetic and collaborative culture where pragmatism meets with bold decision-making. We embrace uncertainty with confidence, guided by our commitment to making a meaningful impact for patients. Our people are trusted and empowered, united by urgency, purpose, and the drive to advance science for patients around the world.  

To learn more about our story and company culture, visit us at https://bridgebio.com 

What You’ll Do 

The Vice President & General Manager, EU North, reporting to the SVP, Head of International, leads BridgeBio’s commercial presence across the Nordic region, the United Kingdom, and Ireland. The role carries full P&L responsibility for the cluster and is accountable for building the organization, shaping the commercial construct, and securing the external relationships required to bring our innovative medicines to patients across these markets, in close coordination with BridgeBio International headquarters in Zurich.

Bringing the Nordics, the United Kingdom, and Ireland under a single leadership mandate is deliberate. The clinical, payer, and advocacy networks that drive rare disease access across these geographies are deeply interconnected — published evidence travels, centers of expertise cross-refer, and national HTA bodies observe one another's decisions. Insight, credibility, and relationships built in one market compound across the cluster. 

The successful candidate will join at the inception phase of our EU North operations, shape the organization from the first hire forward, and define how BridgeBio shows up to patients, clinicians, payers, and policymakers in the cluster for years to come. 

Regional Scope 

The Nordic markets — Sweden, Denmark, Norway, and Finland — are the cluster's operational center of gravity and the immediate focus for launch execution. The General Manager will lead direct launch preparation and execution across these markets, including HTA and reimbursement engagement with TLV, Nye Metoder, Medicinrådet, and Fimea, and will leverage FINOSE-enabled joint pathways where they accelerate patient access. 

In the United Kingdom and Ireland, the General Manager will lead an active pre-launch build, shaping BridgeBio's market access position with NICE, SMC, AWMSG, NHSE commissioning, the Innovative Licensing and Access Pathway, and the NCPE and HSE in Ireland; cultivating the clinical and patient advocacy networks that will anchor our launches; and readying the organization to move to full launch execution as market access conditions permit. If the UK access environment evolves in a way that opens a viable commercial path for a given asset, the General Manager will lead the transition to active launch and will advise international leadership on timing, sequencing, and investment. 

Responsibilities

• Organizational build. Establish the EU North operating entity from inception, including recruitment of the core leadership team, legal and infrastructure set-up, and governance in coordination with International HQ 
• Launch leadership — Nordics. Lead launch planning and execution for infigratinib, encaleret, and subsequent pipeline assets across the Nordic markets, with appropriate sequencing and investment pacing by country 
• Pre-launch leadership — UK & Ireland. Lead BridgeBio's market access engagement, evidence strategy, and organizational readiness in the United Kingdom and Ireland; drive the strategic judgement on when and how to transition to active launch for each asset. 
• P&L ownership. Own the cluster P&L end-to-end — forecasting, investment prioritization, risk management, and performance delivery across launch, pre-launch, and in-line periods. 
• Market access strategy. Develop and execute reimbursement and pricing strategies tailored to each national authority in the cluster, including early scientific advice, evidence planning, managed-entry agreements, and risk-sharing frameworks 
• Clinical opinion leader engagement. Build and sustain durable relationships with the leading cardiologists, endocrinologists, and skeletal dysplasia specialists across the cluster. Ensure BridgeBio is recognized as the scientific and clinical partner of choice in ATTR-CM, achondroplasia, and ADH1/chronic hypoparathyroidism. In rare disease, this is not an activity to delegate — the General Manager will be personally active in this engagement as a senior, credible, and mission-led presence 
• Patient advocacy leadership. Establish BridgeBio as a trusted, long-term partner to rare disease patient organizations across the cluster, spanning the ATTR amyloidosis, achondroplasia, and hypoparathyroidism and ADH1 communities. Recognize that in rare disease, the patient voice is central to access, to policy influence, and to the credibility with which we operate — and lead accordingly 
• Cross-functional integration. Partner closely with Medical Affairs, Regulatory, Market Access, Finance, Legal, Compliance, and Commercial Operations at International HQ to deliver an integrated launch and pre-launch construct across all three geographies 
• Policy and association engagement. Represent BridgeBio externally with integrity, including engagement with national industry associations, compliance frameworks, and broader EU and national policy fora 
• Environmental sensing. Anticipate macroeconomic, political, regulatory, and competitive trends affecting the region and translate them into action for the business 
• Cultural stewardship. Reinforce BridgeBio's core values in every hire, every partnership, and every interaction 

The above job description documents the general nature and level of work but is not intended to be an exhaustive list of activities, duties, and responsibilities required of job incumbents. Therefore, job incumbents are expected to perform all other duties as assigned or required, as training and experience allow.   

Where You'll Work

• This is a role based in Sweden with expected travel of up to 50%

Who You Are

You are a builder. You are comfortable operating before the organization beneath you is fully formed, and you exercise good judgement about which decisions to make yourself, which to delegate, and which to escalate. You are analytically rigorous and commercially sharp, and you bring a patient-first orientation to every strategic choice. 

You are active in external leadership. You understand that in rare diseases, the General Manager does not delegate the relationships that matter most — with the clinicians who treat these patients, with the advocates who speak for them, and with the authorities that decide what patients can access. You enjoy this work, and you are good at it. 

You hold yourself and your team to the highest standards of ethics and compliance, and you understand that trust — with patients, with physicians, with payers, and with colleagues — is BridgeBio's most important asset. 

Experience & Capabilities

• At least ten years in senior commercial leadership roles with P&L responsibility, including at least one direct launch cycle within the EU North cluster (Nordics and/or UK) 
• Commercial launch experience in rare disease, orphan drugs, or specialty medicines, with demonstrated ability to navigate complex HTA and reimbursement environments 
• Deep working knowledge of market access across multiple countries in the cluster — engagement with authorities such as TLV, Nye Metoder, Medicinrådet, Fimea, NICE, SMC, and the NCPE — and experience with managed-access and risk-sharing agreements 
• Demonstrated personal track record of building and sustaining senior KOL and patient advocacy relationships in a rare disease or specialty context 
• Demonstrated ability to build and lead and leading high-performance teams in a start-up, early-affiliate, or greenfield environment 
• Experience operating across functions and geographies within a matrixed international organization 
• Prior launch or commercialization experience in cardiology, endocrinology, or skeletal dysplasia indications 
• Demonstrated capacity to carry both a launch market and a pre-launch market concurrently, with sound judgement on where to invest ahead of revenue 
• Background combining a larger company launch pedigree with a demonstrated capacity to operate in a lean, entrepreneurial setting 
• Fluency in English required. Fluency in one or more additional cluster languages is an asset but not a requirement 

• Market leading compensation 
• Hybrid work model - we value your flexibility in how you work, but encourage time in the office to strengthen our culture, collaboration, and sense of community
• We provide career development through regular feedback, continuous education and professional development programs
• We celebrate strong performance with financial rewards, peer-to-peer recognition, and growth opportunities